| Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling M Felcht, R Luck, A Schering, P Seidel, K Srivastava, J Hu, A Bartol, ... The Journal of clinical investigation 122 (6), 1991-2005, 2012 | 500 | 2012 |
| Pericyte-expressed Tie2 controls angiogenesis and vessel maturation M Teichert, L Milde, A Holm, L Stanicek, N Gengenbacher, S Savant, ... Nature communications 8 (1), 1-12, 2017 | 276 | 2017 |
| Spheroid-based engineering of a human vasculature in mice A Alajati, AM Laib, H Weber, AM Boos, A Bartol, K Ikenberg, T Korff, ... Nature methods 5 (5), 439-445, 2008 | 235 | 2008 |
| Cerebral cavernous malformation protein CCM1 inhibits sprouting angiogenesis by activating DELTA-NOTCH signaling J Wüstehube, A Bartol, SS Liebler, R Brütsch, Y Zhu, U Felbor, U Sure, ... Proceedings of the National Academy of Sciences 107 (28), 12640-12645, 2010 | 205 | 2010 |
| Spheroid-based human endothelial cell microvessel formation in vivo AM Laib, A Bartol, A Alajati, T Korff, H Weber, HG Augustin Nature protocols 4 (8), 1202-1215, 2009 | 160 | 2009 |
| Integrin cytoplasmic domain–associated protein-1 attenuates sprouting angiogenesis R Brütsch, SS Liebler, J Wüstehube, A Bartol, SE Herberich, MG Adam, ... Circulation research 107 (5), 592-601, 2010 | 80 | 2010 |
| Recruitment of human cord blood-derived endothelial colony-forming cells to sites of tumor angiogenesis K Bieback, M Vinci, S Elvers-Hornung, A Bartol, T Gloe, M Czabanka, ... Cytotherapy 15 (6), 726-739, 2013 | 32 | 2013 |
| Can adaptive clinical trials help to solve the productivity crisis of the pharmaceutical industry?-a scenario analysis J Mahlich, A Bartol, S Dheban Health Economics Review 11, 1-10, 2021 | 19 | 2021 |
| Konsensuspapier—Bedarfsgerechte Medikation bei neurologischen und geriatrischen Dysphagie-Patienten F Hanke, T Rittig, D Simonis, A Mohra, I Füsgen, A Riecker MMW-Fortschritte der Medizin 156 (13), 64-71, 2014 | 5 | 2014 |
| Ten years of AMNOG from an oncological perspective: new horizons and continuing expansion A Bartol, K Dressler, P Kaskel, C Landsberg, C Lechner, M Petschulies Journal of Cancer Research and Clinical Oncology 149 (6), 2637-2645, 2023 | 4 | 2023 |
| Tumor vessel associated-pericytes A Bartol, AM Laib, HG Augustin Tumor-Associated Fibroblasts and their Matrix: Tumor Stroma, 91-110, 2011 | 2 | 2011 |
| Ten years of German benefit assessment: price analysis for drugs with unproven additional benefit K Kleining, J Laufenberg, P Thrun, D Ehlert, J Wasem, A Bartol Health Economics, Policy and Law, 1-18, 2023 | 1 | 2023 |
| Zehn Jahre AMNOG-Prozess aus Sicht der Onkologie A Bartol, K Dreßler, P Kaskel, C Landsberg, C Lechner, M Petschulies Forum 37 (1), 84-90, 2022 | 1 | 2022 |
| Innovation durch Kombination: Wie das GKV-Finanzstabilisierungsgesetz den therapeutischen Fortschritt ausbremst A Bartol, K Dreßler, G Isbary, C Lechner, I Niemann, M Petschulies Forum 38 (6), 459-462, 2023 | | 2023 |
| Digitale Innovation nutzen, Daten konsequent nutzen D Wirth, A Bartol, D Brakmann Digitale Gesundheitsanwendungen - Rechtliche Grundlagen, innovative …, 2021 | | 2021 |
Hellmut AugustinEuropean Center for Angioscience, Medical Faculty Mannheim, Heidelberg University & German CancerEmail confirmado em angiogenese.de
